Stock Price Updates, Growth Prospects, and New Obesity Treatment Guidelines - Research Report on Alexion, HCA, Novartis,

Stock Price Updates, Growth Prospects, and New Obesity Treatment Guidelines -
        Research Report on Alexion, HCA, Novartis, LabCorp, and VIVUS

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 28, 2013

NEW YORK, November 28, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), HCA Holdings, Inc. (NYSE: HCA), Novartis
AG (NYSE: NVS), Laboratory Corp. of America Holdings (NYSE: LH), and VIVUS
Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Alexion Pharmaceuticals, Inc. Research Report

On November 25, 2013, Alexion Pharmaceuticals, Inc.'s (Alexion) stock declined
0.50%, ending the day at $122.17. Over the previous three trading sessions,
shares of Alexion increased 2.61% compared to the Nasdaq Composite, which
advanced 1.87% during the same period. The Full Research Report on Alexion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4619_ALXN

--

HCA Holdings, Inc. Research Report

On November 25, 2013, HCA Holdings, Inc.'s (HCA) stock declined 0.92%, ending
the day at $44.35. Over the previous three trading sessions, shares of HCA
gained 0.34% compared to the Dow Jones Industrial Average which increased
1.08% during the same period. The Full Research Report on HCA Holdings, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/be59_HCA

--

Novartis AG Research Report

On November 22, 2013, Novartis AG (Novartis) reported a set of key
developments in the Company. The Company announced the launch of a $5 billion
share buyback, which will commence immediately, and executed over two years on
the 2^nd trading line. The Company also stated that it recently announced a
definitive agreement to divest its blood transfusion diagnostics unit to
Grifols for $1.7 billion. Novartis further reconfirmed its optimal capital
structure with a target rating of double-A. Novartis stated that its
pharmaceuticals division is entering a new growth phase, propelled by
productive R&D engine. Novartis added that it is developing business segments
in Dermatology, Heart Failure, Respiratory and Cell Therapy to complement its
Oncology business. The Company informed that it is on track to grow every year
in the next five years despite loss of exclusivity for Glivec. Novartis also
revealed that Alcon is positioned to deliver above-market growth in the mid to
high-single digits in constant currencies, due to its innovative products
addressing significant patient need. Joseph Jimenez, CEO of Novartis,
commented, "Novartis has reached an inflection point, having fully integrated
Alcon and reduced debt. We are now further sharpening the execution of our
strategy to strengthen shareholder value through science-based innovation in
high-growth segments of healthcare where we have the global scale, competitive
advantage and the right capabilities to win." The Full Research Report on
Novartis AG - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9b6d_NVS

--

Laboratory Corp. of America Holdings Research Report

On November 25, 2013, Laboratory Corp. of America Holdings' (LabCorp) stock
increased 0.65%, ending the day at $105.84. Over the previous three trading
sessions, shares of LabCorp advanced 1.62% compared to the Dow Jones
Industrial Average which gained 1.08% during the same period. The Full
Research Report on Laboratory Corp. of America Holdings - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c267_LH

--

VIVUS Inc. Research Report

On November 21, 2013, VIVUS Inc. (VIVUS) announced its support of new clinical
practice guidelines encouraging healthcare providers to take on a more active
role in an effort to help overweight or obese patients achieve and maintain a
healthy body weight. The Company stated that according to the guidelines,
obesity medication can be considered as an adjunct to lifestyle intervention
to help appropriate patients (individuals with BMI > 30 or BMI > 27 with at
least one obesity-associated comorbid condition) achieve their weight loss
goals. VIVUS stated that the new guidelines were developed by the American
Heart Association, American College of Cardiology and The Obesity Society,
along with the National Heart, Lung and Blood Institute.

Barbara Troupin, MD, Vice President, Scientific Communication and Risk
Management, VIVUS, commented, "Obesity is a complex condition affecting
millions of Americans, and diet and exercise alone are often not enough. VIVUS
supports this new guidance, and encourages physicians to work closely with
patients to find the treatment plans that will help them achieve the benefits
of a lower, healthier weight." The Full Research Report on VIVUS Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8ae9_VVUS

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.